Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin.
Recombinant Salmonella strains expressing foreign heterologous genes have been extensively studied as live oral vaccine delivery vectors. We have investigated the mucosal and systemic immune responses following oral immunization with a recombinant Salmonella enterica serovar Typhimurium expressing the hemagglutinin HagB from Porphyromonas gingivalis, a suspected etiological agent of adult periodontal disease. We have previously shown a primary mucosal and systemic response following oral immunization with chi4072/pDMD1 and recall responses following boosting at 14 weeks after primary immunization. In this study, we examined the effects of earlier boosting as well as the effects of deliberately induced immunity to the Salmonella carrier strain on subsequent immune responses. Mice boosted at week 7 following immunization, a point which corresponded to the peak of the primary response, generally showed lower responses than those boosted at week 14. When mice were preimmunized with the Salmonella carrier alone and then immunized with the recombinant strain 7 or 14 weeks later, significant reductions were seen for serum immunoglobulin G (IgG) antibodies at week 14 and for salivary IgA at week 7. No reductions were seen in serum IgA or vaginal wash IgA antibodies. Mice appear to be refractory to boosting with orally administered salmonellae at 7 weeks. Deliberate immunization with the carrier strain did not appreciably affect recall responses at 14 weeks, with the exception of the serum IgG responses, nor did it affect colonization of the Peyer's patches.
Kohler
J J
JJ
Department of Oral Biology, University of Florida, Gainesville, Florida 32610, USA.
Pathangey
L B
LB
Gillespie
S R
SR
Brown
T A
TA
D018829:Adhesins, Bacterial; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D016866:Bacteroidaceae Infections / Q000517:prevention & control; D005260:Female; D006388:Hemagglutinins / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D037102:Lectins; D051379:Mice; D008807:Mice, Inbred BALB C; D010581:Peyer's Patches / Q000382:microbiology; D016966:Porphyromonas gingivalis / Q000276:immunology*; D012463:Saliva / Q000276:immunology; D012475:Salmonella / Q000276:immunology*; D012486:Salmonella typhimurium / Q000235:genetics; D013154:Spleen / Q000382:microbiology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*; D014621:Vagina / Q000276:immunology
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; C098582:HagB protein, Porphyromonas gingivalis; D006388:Hemagglutinins; D037102:Lectins; D014614:Vaccines, Synthetic